Gilead Company Profile

✉ Email this page to a colleague

GILEAD has thirty approved drugs.

There are eighty-eight US patents protecting GILEAD drugs.

There are two thousand three hundred and twenty-three patent family members on GILEAD drugs in sixty-six countries and three hundred and ninety-seven supplementary protection certificates in nineteen countries.

International Patents:	2323
US Patents:	88
Tradenames:	24
Ingredients:	24
NDAs:	30
Patent Litigation for Gilead:	See patent lawsuits for Gilead
PTAB Cases with Gilead as patent owner:	See PTAB cases with Gilead as patent owner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes	10,065,958*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No	9,296,769	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	TABLET;ORAL	215974-001	Dec 22, 2022		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-002	Mar 10, 2016	6,642,245*PED	⤷ Try a Trial
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-001	Oct 26, 2001	4,808,716	⤷ Try a Trial
Gilead	LETAIRIS	ambrisentan	TABLET;ORAL	022081-002	Jun 15, 2007	7,601,730	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	10 mg	➤ Subscribe	2010-06-08
➤ Subscribe	Tablets	200 mg/300 mg	➤ Subscribe	2008-09-26
➤ Subscribe	Tablets	600 mg/200 mg/300 mg	➤ Subscribe	2008-12-29
➤ Subscribe	Tablets	150 mg, 200 mg, and 250 mg	➤ Subscribe	2012-05-17
➤ Subscribe	Tablets	150 mg, 150 mg, 200 mg, 300 mg	➤ Subscribe	2018-10-04
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2012-07-16
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2015-02-09
➤ Subscribe	Tablets	100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg	➤ Subscribe	2017-05-19
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2010-01-26
➤ Subscribe	Tablets	200 mg/25 mg/300 mg	➤ Subscribe	2015-05-20
➤ Subscribe	Tablets	150 mg	➤ Subscribe	2015-12-09

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1564210	CR 2013 00058	Denmark	⤷ Try a Trial	PRODUCT NAME: ELVITEGRAVIR ELLER ET HYDRAT, ET SOLVAT, EN TAUTOMER ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/830/001-002 20130527
1761540	1790006-9	Sweden	⤷ Try a Trial	PRODUCT NAME: IDELALISIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/14/938 20140919
1419152	19/2012	Austria	⤷ Try a Trial	PRODUCT NAME: RILPIVIRIN UND PHARMAZEUTISCH ANNEHMBARE ADDITIONSSALZE VON RILPIVIRIN, ENSCHLIESSLICH DEM HYDROCHLORID VON RILPIVIRIN; REGISTRATION NO/DATE: EU/1/11/736/001 (MITTEILUNG) 20111130
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.